<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045613</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-CS-201</org_study_id>
    <secondary_id>2019-000359-15</secondary_id>
    <nct_id>NCT04045613</nct_id>
  </id_info>
  <brief_title>Derazantinib and Atezolizumab in Patients With Urothelial Cancer</brief_title>
  <acronym>FIDES-02</acronym>
  <official_title>An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of derazantinib monotherapy or&#xD;
      derazantinib-atezolizumab in combination in patients with advanced urothelial cancer&#xD;
      harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various&#xD;
      clinical stages of disease progression and prior treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises five open-label substudies in patients with advanced urothelial cancer&#xD;
      harboring FGFR GA who will be treated by derazantinib monotherapy or derazantinib in&#xD;
      combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status,&#xD;
      or patients whose disease progressed after either first-line treatment or prior treatment&#xD;
      with FGFR inhibitors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) based on RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of derazantinib 200 mg twice a day with atezolizumab 1200 mg every three weeks</measure>
    <time_frame>After enrollment of the first 10 patients in substudy 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of derazantinib 200 mg twice a day as monotherapy</measure>
    <time_frame>After enrollment of the first 10 patients in substudy 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate per RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response per RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival (PFS) and PFS at 6 months</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS) and OS at 6 months</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of study treatment based on incidence of treatment-emergent adverse events</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Derazantinib monotherapy [Substudy 1]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib + atezolizumab: Dose finding [Substudy 2]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding and dose expansion in patients with solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib + atezolizumab: First line [Substudy 3]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer will be treated with a combination of derazantinib and atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib +/- atezolizumab: Second line [Substudy 4]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomized to receive either derazantinib alone or a combination of derazantinib and atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib monotherapy [Substudy 5]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib dose level 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib dose level 1 (300mg once daily) monotherapy</intervention_name>
    <description>Derazantinib will be administered orally at a dose of 300 mg once per day.</description>
    <arm_group_label>Derazantinib +/- atezolizumab: Second line [Substudy 4]</arm_group_label>
    <arm_group_label>Derazantinib monotherapy [Substudy 1]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib various dose levels in combination with atezolizumab</intervention_name>
    <description>Derazantinib was administered orally at various dose levels and the RP2D of derazantinib in combination with atezolizumab was determined to be 300 mg once per day derazantinib plus 1200 mg atezolizumab every three weeks.</description>
    <arm_group_label>Derazantinib + atezolizumab: Dose finding [Substudy 2]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib dose level 2 (200 mg twice daily) monotherapy</intervention_name>
    <description>Derazantinib will be administered orally at a dose of 200 mg twice daily.</description>
    <arm_group_label>Derazantinib monotherapy [Substudy 5]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib dose level 1 in combination with atezolizumab</intervention_name>
    <description>Derazantinib will be administered orally at a dose of 300 mg once per day in combination with atezolizumab 1200 mg every three weeks.</description>
    <arm_group_label>Derazantinib +/- atezolizumab: Second line [Substudy 4]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib dose level 2 in combination with atezolizumab</intervention_name>
    <description>Derazantinib will be administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every three weeks.</description>
    <arm_group_label>Derazantinib + atezolizumab: First line [Substudy 3]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or&#xD;
             lower urinary tract&#xD;
&#xD;
          -  Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or&#xD;
             progressing disease&#xD;
&#xD;
          -  Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short&#xD;
             variants and rearrangements / fusions)&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of chemotherapy, targeted therapies, immunotherapy, or treatment with an&#xD;
             investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug&#xD;
             whichever is longer before the first dose of study drug.&#xD;
&#xD;
          -  Concurrent evidence of any clinically significant corneal or retinal disorder&#xD;
&#xD;
          -  Phosphatemia greater than institutional upper limit of normal (ULN) at screening&#xD;
&#xD;
          -  Uncontrolled tumor-related hypercalcemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Häckl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica International Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Häckl, MD</last_name>
    <phone>+41 76 302 53 10</phone>
    <email>manuel.haeckl@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Braun, MD</last_name>
    <phone>+41 79 121 15 61</phone>
    <email>stephan.braun@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTCA Clinical Research Inc., Atlanta</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center, Inc. DBA CTCA, Chicago</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Englander Institute Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System - Prisma Health Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center (UTSWMC)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Cancer Care</name>
      <address>
        <city>Birtinya</city>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital and Health Services</name>
      <address>
        <city>Canberra</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital</name>
      <address>
        <city>Tugun</city>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology &amp; Haematology Services</name>
      <address>
        <city>Wendouree</city>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHA Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute Alberta Health Services</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>61700</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Timone / CEPCM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology - Pitié-Salpêtrière Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopole de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkolgiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bacs- Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>B.A.Z.Megyei Központi Kórház és Egyetemi Oktató Kórház</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Europeo di Oncologia IEO</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Valtellina e Alto Lario - UOC Oncologia Medica Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35105</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St. Marys Hospital Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o. o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., 04-073, Warszawa, Poland</name>
      <address>
        <city>Warszawa</city>
        <zip>04-073</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny</name>
      <address>
        <city>Wieliszew</city>
        <zip>05-135</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IOB - Hospital Quiron Salud</name>
      <address>
        <city>Barcelona</city>
        <zip>8023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marques de Valdecilla University Hospital</name>
      <address>
        <city>Santander</city>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>14009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>W1T7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic urothelial cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>Fibroblast Growth Factor Receptor</keyword>
  <keyword>FGFR genetic aberration</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>derazantinib</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>immune checkpoint blockade</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>Tecentriq</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

